0000950170-24-014194.txt : 20240213 0000950170-24-014194.hdr.sgml : 20240213 20240213082939 ACCESSION NUMBER: 0000950170-24-014194 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240213 ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240213 DATE AS OF CHANGE: 20240213 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PRECISION BIOSCIENCES INC CENTRAL INDEX KEY: 0001357874 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38841 FILM NUMBER: 24622699 BUSINESS ADDRESS: STREET 1: 302 EAST PETTIGREW STREET STREET 2: SUITE A-100 CITY: DURHAM STATE: NC ZIP: 27701 BUSINESS PHONE: 919-314-5512 MAIL ADDRESS: STREET 1: 302 EAST PETTIGREW STREET STREET 2: SUITE A-100 CITY: DURHAM STATE: NC ZIP: 27701 8-K 1 dtil-20240213.htm 8-K 8-K
0001357874false--12-31NASDAQ00013578742024-02-132024-02-13

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 13, 2024

 

 

Precision BioSciences, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-38841

20-4206017

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

302 East Pettigrew St.

Suite A-100

 

Durham, North Carolina

 

27701

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 919 314-5512

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.000005 per share

 

DTIL

 

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


 

 

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On February 13, 2024, Precision BioSciences, Inc. (the “Company”) effected a 1-for-30 reverse stock split of its common stock (the “Reverse Stock Split”). As previously disclosed, at its special meeting of stockholders held on January 18, 2024 (the “Special Meeting”), the stockholders of the Company approved a proposal to authorize the Company’s Board of Directors (the “Board”), in its discretion following the Special Meeting, to amend the Company’s Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) to effect a reverse stock split of all of the outstanding shares of the Company’s common stock, par value $0.000005 per share, in a ratio within the range from each whole number between and including ten (10) and thirty (30) (the “Reverse Split Ratios”). On February 6, 2024, following the Special Meeting, the Board approved the Reverse Stock Split at a ratio of 1-for-30. On February 13, 2024, the Company filed with the Secretary of State of the State of Delaware a certificate of amendment (the “Certificate of Amendment”) to amend the Certificate of Incorporation to effect the Reverse Stock Split. The Reverse Stock Split will become effective at 5:00 p.m., Eastern Time, on February 13, 2024.

As a result of the Reverse Stock Split, every 30 shares of the Company’s common stock issued or outstanding were automatically reclassified into one new share of common stock, subject to the treatment of fractional shares as described below, without any action on the part of the holders. Proportionate adjustments will be made to the exercise prices and the number of shares underlying the Company’s outstanding equity awards, as applicable, as well as to the number of shares issuable under the Company’s equity incentive plans and certain existing agreements. The common stock issued pursuant to the Reverse Stock Split remain fully paid and non-assessable. The Reverse Stock Split did not affect the number of authorized shares of common stock or the par value of the common stock.

No fractional shares will be issued in connection with the Reverse Stock Split. Stockholders who would otherwise be entitled to receive fractional shares as a result of the Reverse Stock Split will be entitled to a cash payment in lieu thereof at a price equal to the fraction to which the stockholder would otherwise be entitled multiplied by the closing sales price per share of the common stock (as adjusted to give effect to the Reverse Stock Split) on The Nasdaq Capital Market on February 13, 2024, the last trading day immediately preceding the effective time of the Reverse Stock Split.

Trading of the Company’s common stock on The Nasdaq Capital Market is expected to commence on a split-adjusted basis when the market opens on February 14, 2024, under the existing trading symbol “DTIL.” The new CUSIP number for the Company’s common stock following the Reverse Stock Split is 74019P 207.

The foregoing description of the Certificate of Amendment is qualified in its entirety by reference to the full text of the Certificate of Amendment, a copy of which is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the expected timing of the reverse stock split, the impact of the reverse stock split on the Company’s share price, and the Company’s ability to meet the minimum per share bid price requirement for continued listing on The Nasdaq Capital Market. In some cases, you can identify forward-looking statements by terms such as “aim,” “anticipate,” “approach,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “goal,” “intend,” “look,” “may,” “mission,” “plan,” “possible,” “potential,” “predict,” “project,” “pursue,” “should,” “target,” “will,” “would,” or the negative thereof and similar words and expressions. Forward-looking statements are based on management’s current expectations, beliefs and assumptions and on information currently available to us. Such statements are neither promises nor guarantees, and involve a number of known and unknown risks, uncertainties and assumptions, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including, without limitation, the risks referred to under the section “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023, as any such factors may be updated from time to time in our other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov and the Investors page of our website under SEC Filings at investor.precisionbiosciences.com. All forward-looking statements speak only as of the date of this Current Report on Form 8-K and, except as required by applicable law,

we have no obligation to update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

 

Item 9.01 Financial Statements and Exhibits.

 

 

(d)

Exhibits

Exhibit
No.

Description

3.1

Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Precision BioSciences, Inc., dated February 13, 2024.

 

 

 

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).


 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

PRECISION BIOSCIENCES, INC.

 

 

 

 

Date:

February 13, 2024

By:

/s/Dario Scimeca

 

 

 

Dario Scimeca
General Counsel

 

 EX-3.1 2 dtil-ex3_1.htm EX-3.1 EX-3.1

Exhibit 3.1

CERTIFICATE OF AMENDMENT

TO

AMENDED AND RESTATED CERTIFICATE OF INCORPORATION

OF

PRECISION BIOSCIENCES, INC.

Precision BioSciences, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify as follows:

FIRST: That the Board of Directors of the Corporation duly adopted resolutions recommending and declaring advisable that the Amended and Restated Certificate of Incorporation of the Corporation be amended and that such amendments be submitted to the stockholders of the Corporation for their consideration, as follows:

RESOLVED, that the first sentence of Article FOURTH of the Amended and Restated Certificate of Incorporation be, and hereby is, amended and restated in its entirety to read as follows:

“That, effective at 5:00 p.m., Eastern Time, on the date this Certificate of Amendment to the Amended and Restated Certificate of Incorporation is filed with the Secretary of State of the State of Delaware (the “Effective Time”), a one-for-thirty reverse stock split of the Common Stock (as defined below) shall become effective, pursuant to which each thirty shares of Common Stock issued and held of record by each stockholder of the Corporation (including treasury shares) immediately prior to the Effective Time shall be reclassified and combined into one validly issued, fully paid and nonassessable share of Common Stock automatically and without any action by the holder thereof upon the Effective Time and shall represent one share of Common Stock from and after the Effective Time (such reclassification and combination of shares, the “Reverse Stock Split”). No fractional shares of Common Stock shall be issued as a result of the Reverse Stock Split and, in lieu thereof, (a) with respect to holders of one or more certificates, if any, which formerly represented shares of Common Stock that were issued and outstanding immediately prior to the Effective Time, upon surrender after the Effective Time of such certificate or certificates, any holder who would otherwise be entitled to a fractional share of Common Stock as a result of the Reverse Stock Split, following the Effective Time, shall be entitled to receive a cash payment (the “Fractional Share Payment”) equal to the fraction of which such holder would otherwise be entitled multiplied by the closing price per share of Common Stock as reported by The Nasdaq Stock Market LLC (as adjusted to give effect to the Reverse Stock Split) on the date of the Effective Time; provided that, whether or not fractional shares would be issuable as a result of the Reverse Stock Split shall be determined on the basis of (i) the total number of shares of Common Stock that were issued and outstanding immediately prior to the Effective Time formerly represented by certificates that the holder is at the time surrendering and (ii) the aggregate number of shares of Common Stock after the Effective Time into which the shares of Common Stock formerly represented by such certificates shall have been reclassified; and (b) with respect to holders of shares of Common Stock in book-entry form in the records of the Corporation’s transfer agent that were issued and outstanding immediately prior to the Effective Time, any holder who would otherwise be entitled to a fractional share of Common Stock as a result of the Reverse Stock Split (after aggregating all fractional shares), following the Effective Time, shall be entitled to receive the Fractional Share Payment automatically and without any action by the holder.

 

The total number of shares of all classes of stock which the Corporation shall have authority to issue is 210,000,000 shares, consisting of (a) 200,000,000 shares of Common Stock, $0.000005 par value per share (“Common Stock”), and (b) 10,000,000 shares of Preferred Stock, $0.0001 par value per share (“Preferred Stock”).”

SECOND: That, at a meeting of stockholders of the Corporation, the aforesaid amendment was duly adopted by the stockholders of the Corporation.

THIRD: That the aforesaid amendment was duly adopted in accordance with the applicable provisions of Section 242 of the General Corporation Law of the State of Delaware.

IN WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to be signed by its General Counsel and Secretary on this 13th day of February 2024.

 

PRECISION BIOSCIENCES, INC.

 

By: /s/ Dario Scimeca
Name: Dario Scimeca
Title: General Counsel and Secretary

 

 

 EX-101.SCH 3 dtil-20240213.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink Pre-commencement Issuer Tender Offer Entity Address, State or Province Trading Symbol Soliciting Material Entity Address, City or Town Written Communications Entity Central Index Key CIK Entity Tax Identification Number Entity Registrant Name Registrant Name Current Fiscal Year End Date Entity Ex Transition Period Document Period End Date Period End Date Entity Address, Postal Zip Code Entity Incorporation, State or Country Code Local Phone Number City Area Code Pre-commencement Tender Offer Cover [Abstract] Cover Security Exchange Name Entity Emerging Growth Company Amendment Flag Amendment Securities Act File Number Entity Address, Address Line Two Entity Address, Address Line One Title of 12(b) Security Document Type Document Type XML 4 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Document And Entity Information
Feb. 13, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 13, 2024
Entity Registrant Name Precision BioSciences, Inc.
Entity Central Index Key 0001357874
Current Fiscal Year End Date --12-31
Entity Emerging Growth Company true
Securities Act File Number 001-38841
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 20-4206017
Entity Address, Address Line One 302 East Pettigrew St.
Entity Address, Address Line Two Suite A-100
Entity Address, City or Town Durham
Entity Address, State or Province NC
Entity Address, Postal Zip Code 27701
City Area Code 919
Local Phone Number 314-5512
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Ex Transition Period false
Title of 12(b) Security Common Stock, par value $0.000005 per share
Trading Symbol DTIL
Security Exchange Name NASDAQ
EXCEL 6 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 7 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 8 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 25 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://precisionbiosciences.com/20240213/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports dtil-20240213.htm dtil-20240213.xsd http://xbrl.sec.gov/dei/2023 false false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "dtil-20240213.htm": { "nsprefix": "dtil", "nsuri": "http://precisionbiosciences.com/20240213", "dts": { "inline": { "local": [ "dtil-20240213.htm" ] }, "schema": { "local": [ "dtil-20240213.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "keyStandard": 25, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 4, "http://xbrl.sec.gov/dei/2023": 4 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 26, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 25 }, "report": { "R1": { "role": "http://precisionbiosciences.com/20240213/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_e4728840-f932-49ce-9162-12c9283200f9", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "dtil-20240213.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e4728840-f932-49ce-9162-12c9283200f9", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "dtil-20240213.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://precisionbiosciences.com/20240213/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://precisionbiosciences.com/20240213/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://precisionbiosciences.com/20240213/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://precisionbiosciences.com/20240213/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://precisionbiosciences.com/20240213/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://precisionbiosciences.com/20240213/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://precisionbiosciences.com/20240213/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://precisionbiosciences.com/20240213/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://precisionbiosciences.com/20240213/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://precisionbiosciences.com/20240213/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://precisionbiosciences.com/20240213/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "CIK", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://precisionbiosciences.com/20240213/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://precisionbiosciences.com/20240213/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://precisionbiosciences.com/20240213/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://precisionbiosciences.com/20240213/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://precisionbiosciences.com/20240213/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://precisionbiosciences.com/20240213/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://precisionbiosciences.com/20240213/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://precisionbiosciences.com/20240213/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://precisionbiosciences.com/20240213/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://precisionbiosciences.com/20240213/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://precisionbiosciences.com/20240213/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://precisionbiosciences.com/20240213/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://precisionbiosciences.com/20240213/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://precisionbiosciences.com/20240213/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0000950170-24-014194-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-014194-xbrl.zip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end XML 15 dtil-20240213_htm.xml IDEA: XBRL DOCUMENT 0001357874 2024-02-13 2024-02-13 0001357874 false --12-31 NASDAQ 8-K 2024-02-13 Precision BioSciences, Inc. DE 001-38841 20-4206017 302 East Pettigrew St. Suite A-100 Durham NC 27701 919 314-5512 false false false false Common Stock, par value $0.000005 per share DTIL true false